Daliresp (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the Daliresp drug offered from AstraZeneca Pharmaceuticals LP. This Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
| NON-PROPRIETARY NAME: | roflumilast |
| SUBSTANCE NAME: | ROFLUMILAST |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-07-01 |
| END MARKETING DATE: | 0000-00-00 |
Daliresp HUMAN PRESCRIPTION DRUG Details:
| Item Description | Daliresp from AstraZeneca Pharmaceuticals LP |
| LABELER NAME: | AstraZeneca Pharmaceuticals LP |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 500(ug/1) |
| START MARKETING DATE: | 2015-07-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0310-0095_189ded65-63aa-4463-a1e1-1e7c9d687094 |
| PRODUCT NDC: | 0310-0095 |
| APPLICATION NUMBER: | NDA022522 |
Other ROFLUMILAST Pharmaceutical Manufacturers / Labelers:
